期刊
JOURNAL OF HEPATOLOGY
卷 65, 期 5, 页码 1031-1042出版社
ELSEVIER
DOI: 10.1016/j.jhep.2016.05.035
关键词
Liver cancer; Deep sequencing; Mutation; Genomics; Signature
资金
- American Association for the Study of Liver Diseases Foundation Alan Hofmann Clinical and Translational Research Award
Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, both clinically and from a molecular standpoint. The advent of next-generation sequencing technologies has provided new opportunities to extensively analyze molecular defects in HCC samples. This has uncovered major cancer driver genes and associated oncogenic pathways operating in HCC. More sophisticated analyses of sequencing data have linked specific nucleotide patterns to external toxic agents and defined so-called 'mutational signatures' in HCC. Molecular signatures, taking into account intra- and inter-tumor heterogeneity, and their functional validation could provide useful data to predict treatment response to molecular therapies. In this review we will focus on the current knowledge of deep sequencing in HCC and its foreseeable clinical impact. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据